Annovis Bio, Inc. 2025 Annual Report: Key Highlights and Critical Investor Insights

Annovis Bio, Inc. (“Annovis”, NYSE: ANVS) has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This report provides an in-depth look at the company’s financial position, risk factors, and strategic outlook as it navigates the high-stakes world of pharmaceutical research and development.

Key Highlights for Investors

• Going Concern Warning: There is substantial doubt about Annovis Bio’s ability to continue as a going concern. The company’s auditor has included an explanatory paragraph in their opinion citing Annovis’s recurring operating losses and accumulated deficit as significant issues. This is a critical flag for investors and could materially impact the company’s share price.
• History of Significant Losses: Annovis has incurred significant net losses since inception and expects to continue reporting losses for the foreseeable future. The company may never achieve or maintain profitability, putting additional risk on shareholders, especially those seeking near-term returns.
• Need for Substantial Additional Capital: The company will require substantial additional funding to continue operations and to progress its product candidates through the development and commercialization phases. If Annovis fails to secure necessary funding, it may not be able to complete the development and commercialization of its products.
• Limited Operating History and Lack of Commercialization: Annovis has a limited operating history and has never commercialized a pharmaceutical product. This further amplifies investment risk.
• Dependence on a Single Lead Candidate: The company’s success is heavily dependent on the advancement and approval of its lead product candidate, buntanetap. Any setback or failure in its clinical or regulatory progress could have a material adverse effect on Annovis’s prospects and share price.
• Market and Economic Volatility: Unstable market and economic conditions could negatively affect Annovis’s business, financial condition, and stock price. This includes the risk of reduced access to capital markets.
• Product Development and Regulatory Risks: Annovis is subject to all the risks inherent in the drug development process, including the uncertainty of clinical trial results, regulatory approvals, and market acceptance. The company cautions that preclinical and early clinical results may not be indicative of outcomes in later-stage trials, and interim “top-line” data may change upon further analysis.
• Reliance on Third Parties: The company’s operations depend on third-party organizations for many critical functions, including manufacturing, clinical testing, and commercialization. Any issues with these partners could impact Annovis’s ability to advance its pipeline.
• Potential for Securities Litigation: Annovis has previously been subject to securities class action litigation and could face similar lawsuits in the future, which could result in substantial costs and management distraction.
• Stock Volatility: Annovis’s share price has shown significant volatility in the past and may continue to do so, posing risks for both short- and long-term investors.

Financial and Capital Market Data

• Public Float: As of June 30, 2025, the aggregate market value of Annovis’s common stock held by non-affiliates was \$36,076,450, based on the NYSE closing price.
• Shares Outstanding: As of March 12, 2026, Annovis had 28,355,262 shares of common stock outstanding.
• Listing: Annovis’s common stock trades on the New York Stock Exchange under the symbol ANVS.

Summary of Principal Risks That May Affect Share Value

• Ability to Continue as a Going Concern: Any failure to secure necessary funding or achieve positive results from clinical trials could lead to insolvency or bankruptcy, which would likely result in a total loss for shareholders.
• Clinical Trial and Regulatory Uncertainty: Delays, failures, or negative outcomes in clinical trials or regulatory processes for buntanetap or other product candidates could lead to significant share price declines.
• Market Risks: Adverse economic conditions, poor market acceptance of products, or reliance on third parties could negatively affect financial performance and share value.
• Litigation and Compliance Risks: Any litigation or regulatory action could result in financial penalties, business limitations, or management distraction.

Forward-Looking Statements and Cautions

The Annual Report contains numerous forward-looking statements regarding Annovis’s plans, prospects, and expectations. These statements are subject to substantial risks and uncertainties, and actual results may differ materially from those projected. Investors are cautioned not to rely unduly on such statements and are encouraged to review the full “Risk Factors” section in the company’s 10-K for a detailed discussion.

What Shareholders Must Know

• The company’s ability to continue as a going concern is in question. Shareholders must closely monitor the company’s funding activities and any updates on its lead product candidate buntanetap.
• Negative developments in clinical or regulatory progress could have a rapid and significant negative effect on the share price.
• Given Annovis’s history of losses, lack of profitable operations, and the high risks involved in drug development, this is a speculative and high-risk investment at this stage.

Conclusion

The Annovis Bio, Inc. 2025 Annual Report reveals a company facing considerable challenges and risks, particularly with its ability to remain a going concern and its need for substantial additional capital. The outlook is highly dependent on the success of buntanetap and the company’s ability to achieve positive clinical and regulatory milestones. Both existing and prospective shareholders should weigh these risks carefully, as developments—positive or negative—could have a swift and significant impact on Annovis’s share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full official filings and consult with a qualified financial advisor before making any investment decisions. All investments are subject to risk, including the potential loss of principal.

View Annovis Bio, Inc. Historical chart here